Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03747042 · ClinicalTrials.gov registry record · Phase 2
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
A Phase 2 study of Breast Cancer Female, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT03747042: Completed Phase 2 study of Breast Cancer Female, sponsored by University of Texas Southwestern Medical Center.
NCT03747042 is a Phase 2 study of Breast Cancer Female that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 61 participants, below the 691-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03747042, a Phase 2 study of Breast Cancer Female, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
A short pre-surgical non-therapeutic trial involving postmenopausal women with newly diagnosed eR+, HeR2-negative operable breast cancers. After undergoing a core needle biopsy for tissue acquisition, study participants will take a 7- to 30-day (1-4 weeks) course of letrozole in accordance with standard of care. They will then undergo definitive surgical resection of their primary tumor (mastectomy vs lumpectomy) as per standard of care guidelines.
Primary Outcome
Ki67 index measured 1-4 weeks after therapy with letrozole to segregate hormone receptor-positive breast cancers that are highly hormone-dependent vs. those that are not
Conditions Studied
Interventions
- DRUG Letrozole
Study Locations (1)
Texas
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 2 |
What the finished NCT03747042 record still lists
NCT03747042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 691-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which Letrozole is the first listed.
NCT03747042 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03747042 about?
NCT03747042 is a clinical study titled "Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer". A short pre-surgical non-therapeutic trial involving postmenopausal women with newly diagnosed eR+, HeR2-negative operable breast cancers. After undergoing a core needle biopsy for tissue acquisition, study participants will take a 7- to 30-day (1-4 weeks) course of letrozole in accordance with stan...
What is the current status of trial NCT03747042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2018-11-27. Estimated completion is 2025-02-24.
What conditions does trial NCT03747042 study?
This clinical trial studies the following conditions: Breast Cancer Female.
What interventions are being tested in trial NCT03747042?
The interventions under investigation include: Letrozole (DRUG).
Who is sponsoring clinical trial NCT03747042?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03747042 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03747042's enrollment target sits among peer trials
61 30th of 46 higher than 17 of 46 other Breast Cancer Female trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Female trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Microbiome and Association With Implant Infections
RECRUITING · Phase 2
-
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RECRUITING · Phase 2
-
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
RECRUITING · Phase 2
-
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI